SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bodó, I. Articles by Sadler, J. E. Search for Related Content PubMed PubMed Citation Articles by Bodó, I. Articles by Sadler, J. E. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 November 2001, Vol. 98, No. 10, pp. 2973-2979 HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins Imre Bodó, Akira Katsumi, Elodee A. Tuley, Jeroen C. J. Eikenboom, Zhengyu Dong, and J. Evan Sadler From the Howard Hughes Medical Institute and the Departments of Medicine, Biochemistry, and Molecular Biophysics, Washington University School of Medicine, St Louis, MO; and the Department of Hematology, Hemostasis and Thrombosis Research Center, Leiden University Medical Center, The Netherlands. Some families affected by von Willebrand disease type 1 show high penetrance with exceptionally low von Willebrand factor (VWF) levels. Previously, a mutation associated with this dominant phenotype, Cys1149Arg, was found to decrease the secretion of coexpressed normal VWF, and the mutation was proposed to cause intracellular retention of pro-VWF heterodimers. To demonstrate heterodimer formation, a model was developed in which subunits could be distinguished immunologically and by size. Recombinant VWF lacking domain A1 (dA1), A3 (dA3), or both (dA13) was secreted efficiently as a full range of multimers. Cotransfection of Cys1149Arg and dA13 resulted in the secretion of multimeric VWF containing about 250 kd (Cys1149Arg) and about 210 kd (dA13). Cell lysates contained pro-VWF forms of Cys1149Arg and dA13. Immunoprecipitation with an antidomain A1 antibody recovered both subunits in heterodimers, and subunit ratios were consistent with random dimerization. Similar results were obtained for cotransfection of Cys1149Arg and dA1. Normal VWF has a Cys1149-Cys1169 intrachain bond. When cotransfected with normal VWF, Cys1149Arg or the double mutant Cys1149Arg+Cys1169Ser caused a similar decrease in VWF secretion, suggesting that an unpaired Cys1169 does not explain the intracellular retention of Cys1149Arg. VWF Cys1149Arg was not secreted from BHK cells but was degraded intracellularly within about 4 hours, and the proteasome inhibitor lactacystin delayed its clearance more than 16 hours. Thus, dominant von Willebrand disease type 1 may be caused by heterodimerization of mutant and normal subunits in the endoplasmic reticulum followed by proteasomal degradation in the cytoplasm. A similar dominant negative mechanism could cause quantitative deficiencies of other multisubunit proteins. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. L. Haberichter, G. Castaman, U. Budde, I. Peake, A. Goodeve, F. Rodeghiero, A. B. Federici, J. Batlle, D. Meyer, C. Mazurier, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD) Blood, May 15, 2008; 111(10): 4979 - 4985. [Abstract] [Full Text] [PDF] R.-H. Huang, Y. Wang, R. Roth, X. Yu, A. R. Purvis, J. E. Heuser, E. H. Egelman, and J. E. Sadler Assembly of Weibel Palade body-like tubules from N-terminal domains of von Willebrand factor PNAS, January 15, 2008; 105(2): 482 - 487. [Abstract] [Full Text] [PDF] A. R. Purvis, J. Gross, L. T. Dang, R.-H. Huang, M. Kapadia, R. R. Townsend, and J. E. Sadler Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi PNAS, October 2, 2007; 104(40): 15647 - 15652. [Abstract] [Full Text] [PDF] M. Lorenz, B. Hewing, J. Hui, A. Zepp, G. Baumann, A. Bindereif, V. Stangl, and K. Stangl Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity FASEB J, May 1, 2007; 21(7): 1556 - 1564. [Abstract] [Full Text] [PDF] J. J. Michiels, H. H. D. M. van Vliet, Z. Berneman, A. Gadisseur, M. van der Planken, W. Schroyens, A. van der Velden, and U. Budde Intravenous DDAVP and Factor VIII-von Willebrand Factor Concentrate for the Treatment and Prophylaxis of Bleedings in Patients With von Willebrand Disease Type 1, 2 and 3 Clinical and Applied Thrombosis/Hemostasis, January 1, 2007; 13(1): 14 - 34. [Abstract] [PDF] P. D. James, C. Notley, C. Hegadorn, J. Leggo, A. Tuttle, S. Tinlin, C. Brown, C. Andrews, A. Labelle, Y. Chirinian, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study Blood, January 1, 2007; 109(1): 145 - 154. [Abstract] [Full Text] [PDF] J. J. Michiels, Z. Berneman, A. Gadisseur, M. van der Planken, W. Schroyens, A. van de Velde, and H. van Vliet Characterization of Recessive Severe Type 1 and 3 von Willebrand Disease (VWD), Asymptomatic Heterozygous Carriers Versus Bloodgroup O-Related von Willebrand Factor Deficiency, and Dominant Type 1 VWD. Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 277 - 295. [Abstract] [PDF] D. V. Kravtsov, P. E. Monahan, and D. Gailani A classification system for cross-reactive material-negative factor XI deficiency Blood, June 15, 2005; 105(12): 4671 - 4673. [Abstract] [Full Text] [PDF] A. R. Purvis and J. E. Sadler A Covalent Oxidoreductase Intermediate in Propeptide-dependent von Willebrand Factor Multimerization J. Biol. Chem., November 26, 2004; 279(48): 49982 - 49988. [Abstract] [Full Text] [PDF] D. V. Kravtsov, W. Wu, J. C. M. Meijers, M.-F. Sun, M. A. Blinder, T. P. Dang, H. Wang, and D. Gailani Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain Blood, July 1, 2004; 104(1): 128 - 134. [Abstract] [Full Text] [PDF] L. A. O'Brien, P. D. James, M. Othman, E. Berber, C. Cameron, C. R. P. Notley, C. A. Hegadorn, J. J. Sutherland, C. Hough, G. E. Rivard, et al. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease Blood, July 15, 2003; 102(2): 549 - 557. [Abstract] [Full Text] [PDF] C. Wu, F. Wu, J. Pan, J. Morser, and Q. Wu Furin-mediated Processing of Pro-C-type Natriuretic Peptide J. Biol. Chem., July 3, 2003; 278(28): 25847 - 25852. [Abstract] [Full Text] [PDF] J. E. Sadler Von Willebrand disease type 1: a diagnosis in search of a disease Blood, March 15, 2003; 101(6): 2089 - 2093. [Abstract] [Full Text] [PDF] J. B. Rosenberg, S. L. Haberichter, M. A. Jozwiak, E. A. Vokac, P. A. Kroner, S. A. Fahs, Y. Kawai, and R. R. Montgomery The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF Blood, August 13, 2002; 100(5): 1699 - 1706. [Abstract] [Full Text] [PDF] G. Castaman, F. Rodeghiero, P. M. Mannucci, A. Casonato, E. Pontara, F. Sartorello, M. G. Cattini, and A. Girolami The elusive pathogenesis of von Willebrand disease Vicenza Blood, May 13, 2002; 99(11): 4243 - 4245. [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020